Lv4
508 积分 2023-11-19 加入
Development of ICT01, a first-in-class, anti-BTN3A antibody for activating Vγ9Vδ2 T cell–mediated antitumor immune response
1个月前
已完结
Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1/2 study
1个月前
已完结
Breaking barriers: the emerging promise of CAR-T cell therapy in solid tumors
1个月前
已完结
Who wins the combat, CAR or TCR?
1个月前
已完结
肺孢子菌肺炎的临床研究进展
4个月前
已完结
Assessment of Riociguat-related adverse events: a disproportionality analysis utilizing the FDA adverse event reporting system database
5个月前
已完结
Assessment of Riociguat-related adverse events: a disproportionality analysis utilizing the FDA adverse event reporting system database
5个月前
已完结
CAR-redirected natural killer T cells demonstrate superior antitumor activity to CAR-T cells through multimodal CD1d-dependent mechanisms
6个月前
已完结
Optimizing CAR T cell therapy for solid tumours: a clinical perspective
6个月前
已完结
Assessment of Riociguat-related adverse events: a disproportionality analysis utilizing the FDA adverse event reporting system database
7个月前
已完结
皖公网安备34019202002308
